Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism
The One-carbon Therapeutics team is proud and excited to share our latest paper published inNature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitorTH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificityand emphasises the importance of utilising correct human-like conditions and cancer models in drugdevelopment. We show that cancer-specific […]
